Adicet Bio, Inc.

Adicet Bio, Inc. reported a net loss of $116.8 million for the fiscal year ended December 31, 2025, consistent with the prior year's net loss of $117.1 million. The company generated no revenue and incurred total operating expenses of $122.1 million, primarily driven by research and development costs of $99.1 million and general and administrative expenses of $23.0 million. The loss from operations was $122.1 million, partially offset by interest income of $5.8 million. As of December 31, 2025, the company held $158.5 million in cash, cash equivalents, and short-term investments, which it believes is sufficient to fund operations into the second half of 2027. The company's business remains focused on the clinical development of its allogeneic gamma delta T cell therapies, including its lead candidate prula-cel for autoimmune diseases.

Key Takeaways